This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Fulranumab

Amgen, Inc.

Drug Names(s): AMG 403, JNJ-42160443, AMG403

Description: JNJ-42160443 is a fully human monoclonal antibody that binds to and antagonizes nerve growth factor (NGF). NGF controls expression of pain mediators in nerve terminals.

Deal Structure: Amgen and Takeda
In February 2008, Amgen and Takeda Pharmaceutical announced an agreement under which Takeda will develop and commercialize for the Japanese market up to 13 molecules from Amgen's pipeline, one of which is included as an option. The collaboration includes early to mid-stage clinical-stage candidates across a range of therapeutic areas, including oncology, inflammation, and pain.

The financial terms include an upfront cash payment to Amgen of $200 million. Takeda will also pay to Amgen up to $340 million in expected worldwide development costs for these molecules over the next several years, $362 million in success-based milestone payments, and double digit royalties on sales in Japan. Additionally, Takeda plans to acquire all the shares of Amgen's Japanese subsidiary, Amgen KK.

In June 2016, Takeda Pharmaceutical announced revisions on an existing collaboration agreement, under which Takeda had rights to develop and commercialize multiple...See full deal structure in Biomedtracker


Fulranumab News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug